velpatasvir and sofosbuvir

FDA Drug Profile

velpatasvir and sofosbuvir is listed in the FDA National Drug Code directory with 1 NDC code. Available dosage form: tablet, film coated.

Drug details

Generic Name
velpatasvir and sofosbuvir
Sponsor
Patheon Inc.
NDC Codes
1
Dosage Forms
TABLET, FILM COATED
Active Ingredients
VELPATASVIR, SOFOSBUVIR

Indications and Usage

1 INDICATIONS AND USAGE Sofosbuvir and velpatasvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4 ) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin. Sofosbuvir and velpatasvir is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection ( 1 ): without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.